Subcutaneous methotrexate in patients with moderate to severe psoriasis: a critical appraisal.
CONCLUSIONS: Warren et al conclude that the 52-week risk-benefit profile of subcutaneous methotrexate is favourable in patients with psoriasis. This article is protected by copyright. All rights reserved.
PMID: 29399784 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tsakok T, Jabbar-Lopez ZK, Smith CH Tags: Br J Dermatol Source Type: research
More News: Dermatology | Folic Acid | France Health | Germany Health | Methotrexate | Netherlands Health | Psoriasis | Skin | Skin Biopsy | Study | UK Health | Vitamin B9